HK1097194A1 - Liposomal formulations of anthracycline agents and cytidine analogs - Google Patents

Liposomal formulations of anthracycline agents and cytidine analogs

Info

Publication number
HK1097194A1
HK1097194A1 HK07104820.1A HK07104820A HK1097194A1 HK 1097194 A1 HK1097194 A1 HK 1097194A1 HK 07104820 A HK07104820 A HK 07104820A HK 1097194 A1 HK1097194 A1 HK 1097194A1
Authority
HK
Hong Kong
Prior art keywords
liposomal formulations
liposomes
cytarabine
daunorubicin
cytidine analogs
Prior art date
Application number
HK07104820.1A
Other languages
English (en)
Inventor
Lawrence Mayer
Sharon Johnstone
Troy Harasym
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of HK1097194A1 publication Critical patent/HK1097194A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HK07104820.1A 2004-04-22 2007-05-04 Liposomal formulations of anthracycline agents and cytidine analogs HK1097194A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56521004P 2004-04-22 2004-04-22
PCT/CA2005/000625 WO2005102359A1 (en) 2004-04-22 2005-04-22 Liposomal formulations of anthracycline agents and cytidine analogs

Publications (1)

Publication Number Publication Date
HK1097194A1 true HK1097194A1 (en) 2007-06-22

Family

ID=35196733

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07104820.1A HK1097194A1 (en) 2004-04-22 2007-05-04 Liposomal formulations of anthracycline agents and cytidine analogs

Country Status (12)

Country Link
US (2) US8022279B2 (el)
EP (2) EP1744764B1 (el)
JP (1) JP4972545B2 (el)
AU (1) AU2005235455B2 (el)
CA (1) CA2564542C (el)
CY (2) CY1113012T1 (el)
ES (1) ES2388064T3 (el)
HK (1) HK1097194A1 (el)
IL (1) IL178779A (el)
NL (1) NL300960I2 (el)
PT (1) PT1744764E (el)
WO (1) WO2005102359A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213183A1 (en) * 2004-09-20 2008-09-04 Marcel Bally Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin
US9943481B2 (en) * 2005-05-26 2018-04-17 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
HUE058334T2 (hu) * 2007-02-16 2022-07-28 Rotalec Ip Holdings Llc Rögzített gyógyszerarányok hematopoietikus rákok és proliferatív rendellenességek kezelésére
EP2257310A2 (en) * 2008-02-26 2010-12-08 Nerviano Medical Sciences S.r.l. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
KR20220141906A (ko) * 2011-10-21 2022-10-20 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
WO2013151774A1 (en) 2012-04-04 2013-10-10 Halozyme, Inc. Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
LT2846809T (lt) * 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
MX2017014130A (es) 2015-05-04 2018-07-06 Versantis AG Metodo para preparar vesiculas con gradiente de ph de transmembrana.
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法
SG11201804020YA (en) 2015-11-11 2018-06-28 Celator Pharmaceuticals Inc Assays and methods for selecting a treatment regimen for a subject with leukemia
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR20200027548A (ko) * 2017-07-09 2020-03-12 바이오사이트 리미티드 병용 암 요법
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (el) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
DE60237162D1 (de) * 2001-10-03 2010-09-09 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
CN1798544A (zh) * 2003-04-02 2006-07-05 塞拉特药物股份有限公司 喜树碱和氟嘧啶的组合物
US20060165744A1 (en) 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations

Also Published As

Publication number Publication date
CA2564542A1 (en) 2005-11-03
EP1744764A4 (en) 2009-04-01
IL178779A0 (en) 2007-05-15
CY1113012T1 (el) 2016-04-13
IL178779A (en) 2013-12-31
JP2007533670A (ja) 2007-11-22
WO2005102359A8 (en) 2005-12-15
CY2018033I1 (el) 2019-07-10
NL300960I2 (nl) 2019-05-22
AU2005235455A1 (en) 2005-11-03
EP2407169A1 (en) 2012-01-18
US20120009252A1 (en) 2012-01-12
US8022279B2 (en) 2011-09-20
EP1744764A1 (en) 2007-01-24
US20070286897A1 (en) 2007-12-13
ES2388064T3 (es) 2012-10-08
JP4972545B2 (ja) 2012-07-11
CY2018033I2 (el) 2019-07-10
CA2564542C (en) 2012-11-27
US8431806B2 (en) 2013-04-30
AU2005235455B2 (en) 2011-01-20
WO2005102359A1 (en) 2005-11-03
PT1744764E (pt) 2012-08-30
EP1744764B1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
HK1097194A1 (en) Liposomal formulations of anthracycline agents and cytidine analogs
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
EP1283054A4 (en) MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
IL154342A0 (en) A method of analgesia
MY132073A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005105141A3 (en) Combined meningococcal conjugates with common carrier protein
EP1819227A4 (en) PHARMACEUTICAL FORMULATION OF DECITABINE
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
SG153830A1 (en) Galenic formulations of organic compounds
ATE399171T1 (de) Camptothecinanaloge und deren zubereitungsmethoden
WO2005023294A3 (en) Polyacetal drug conjugates as release system
WO2003000194A3 (en) Thienopyridine and thienopyrimidine anticancer agents
PL310344A1 (en) Lyposome containing therapeutic preparations for administration by injection
JP2003509349A5 (el)
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2008095144A3 (en) Controlled release of actives in skin
PL361426A1 (en) Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
EP1177791A3 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
BR0013642A (pt) Análogos de nucleosìdeo de pirrolo[2,3-d]pirimidina
JP2004502732A5 (el)
WO2006095363A3 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts
WO2009052491A3 (en) Fenoldopam formulations and prodrug derivatives
WO2004058140A3 (en) Non-pegylated long-circulating liposomes
WO2004110497A3 (en) Mitomycin conjugates cleavable by thiols
IS6919A (is) Stöðug lyfjablanda sem felur í sér torsemíð afbrigði II